Overview

* ALX Oncology ( ALXO ) Q3 net loss narrows to $22.1 mln, driven by reduced R&D expenses

* Appointed Barbara Klencke, M.D., as interim Chief Medical Officer

Outlook

* Company expects cash runway to last into Q1 2027

* ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026

* Initial safety data for ALX2004 expected in 1H 2026

Result Drivers

* R&D EXPENSES - Reduced R&D expenses contributed to a narrower net loss for the quarter

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.41

Q3 Net -$22.14

Income mln

Q3 Basic -$0.41

EPS

Q3 -$22.53

Income mln

from

Operatio

ns

Q3 $22.53

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for ALX Oncology Holdings Inc ( ALXO ) is $3.00, about 60.7% above its November 6 closing price of $1.18

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)